Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade

Moderna (MRNA) shares closed down 1.9% in the latest session, underperforming the S&P 500, yet the stock has surged 29.08% over the past month. Ahead of its August 1, 2025 earnings, consensus estimates project a quarterly EPS of -$2.99 (up 10.21% YoY) but a significant revenue decline of 47.23% to $127.17 million. Full-year forecasts also indicate substantial revenue contraction, and the Zacks Consensus EPS estimate has seen a 2.46% decline over the last month, resulting in a current Zacks #3 (Hold) Rank.

Analysis

Moderna (MRNA) presents a conflicting picture for investors, characterized by strong recent stock performance juxtaposed with deteriorating forward-looking fundamentals. While the stock has surged 29.08% over the past month, significantly outpacing both the Medical sector's 2.39% gain and the S&P 500's 5.71% rise, it experienced a 1.9% decline in the most recent session. The core concern stems from consensus estimates for its upcoming earnings report on August 1, 2025. Projections indicate a severe year-over-year revenue contraction of 47.23% to $127.17 million for the quarter and a 35.73% decline for the full year. Although the forecasted quarterly EPS of -$2.99 marks a 10.21% improvement from the prior year's quarter, suggesting potential cost controls, the full-year earnings estimate calls for a 13.3% decline. Underscoring this cautious outlook, the Zacks Consensus EPS estimate has been revised downward by 2.46% over the past month, a negative indicator of short-term business trends. The resulting Zacks Rank of #3 (Hold) appropriately reflects this ambiguity, balancing the stock's recent momentum against weakening revenue and earnings forecasts.

Key Decisions for Investors

• Investors should approach the recent 29.08% monthly rally with caution, as it contrasts sharply with forecasts of significant revenue declines of 47.23% for the upcoming quarter and 35.73% for the full year.
• The upcoming August 1, 2025, earnings report is a critical catalyst; focus on management's revenue guidance and commentary on profitability drivers, as the current outlook is predominantly negative.
• Given the 2.46% downward revision in consensus EPS estimates over the last month, continued negative analyst revisions could foreshadow a stall in the stock's momentum and validate the current 'Hold' rating.